Day One Biopharmaceutical Q2 EPS $(0.61), Inline
Portfolio Pulse from Benzinga Newsdesk
Day One Biopharmaceutical (NASDAQ:DAWN) reported Q2 losses of $(0.61) per share, meeting analyst consensus estimates. This represents a 1.67% increase in losses compared to the same period last year.
August 07, 2023 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Day One Biopharmaceutical reported Q2 losses in line with analyst estimates, but the losses increased by 1.67% compared to the same period last year.
Day One Biopharmaceutical's Q2 losses were in line with analyst estimates, which may not significantly impact the stock price. However, the fact that losses increased by 1.67% compared to the same period last year could negatively impact investor sentiment and potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100